MedTrace Logo

Percentage Visualized Mucosa as a Marker for the Quality of Colonoscopy

NCT04482452 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2020-07-22

No results posted yet for this study

Summary

Primary hypothesis: The percentage of mucosa visualized during the withdrawal of a colonoscopy with reference to the position in the colon by means of the scope-guide is an appropriate parameter for assessment of the quality of colonoscopy and correlates with the probability of the detection of adenomas.

Secondary hypothesis:

The investigators hypothesize that the percentage of visualized mucosa differs according patient specific parameters (e.g. gender, age, BMI, bowel preparation), procedure specific parameters (e.g. patient position, device, buscopan, fentanyl, withdrawal time) and investigator specific parameters (professional experience as resident and consultant).

Study Procedure/Evaluation:

The endoscopic images and scope guide from colonoscopy of 500 patients will be filmed. The investigators will correlate the detection of at least one adenoma in the cohort of included patients with the percentage of visualized mucosa during the withdrawal of a colonoscopy. Additional endpoints concerning the quality of the colonoscopy will be assessed as well.

Conditions

  • Colonoscopy

Interventions

PROCEDURE

Colonoscopy

Diagnostic colonoscopy will be performed

Sponsors & Collaborators

  • Insel Gruppe AG, University Hospital Bern

    lead OTHER

Principal Investigators

  • Benjamin Misselwitz, Prof. · Insel Gruppe AG, University Hospital Bern

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-06-08
Primary Completion
2022-05-19
Completion
2022-05-19

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04482452 on ClinicalTrials.gov